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BACKGROUND The purpose of this study was to investigate safety
and efﬁcacy of transcatheter aortic valve implantation (TAVI) in pa-
tients with very small body size.
METHODS Between October 2013 and July 2014, 108 patients from
Japanese multi center TAVI registry were studied. Patients with a very
small body surface area (BSA, &1.40 m2) were deﬁned as the “VSB”
group (n¼54) and the remaining normal BSA patients as the “NB”
group (n¼54).
RESULTS Patients with VSB were older and female patients compared
with NB (86yrs [interquartile range (IQR) 83-88] vs 83yrs [IQR 80-86],
p<0.01; 98.1% vs 48.1%, p<0.01, respectively). In the VSB group,
calculated average annulus diameter and right femoral artery diam-
eter by CT were signiﬁcantly smaller (21.61.6mm vs. 22.51.6mm,
P<0.01, 6.5mm [IQR 5.9-6.8] vs. 6.7mm [IQR 6.0-7.2], p¼0.01,
respectively). The transapical (TA) approach and the 23mm SapienXT
valve were frequently used among VSB group (22.2% vs. 7.4%,
p¼0.03; 77.8% vs. 44.4%, p<0.01, respectively). Equivalent device
success and 30-day survival rates (100% vs. 96.3%, P¼0.25; 100% vs.
96.3%, P¼0.25) were achieved in both groups. Major vascular
complication and mean pressure gradient did not have signiﬁcant
difference in two groups (5.6% vs. 0%, P¼0.12; 10.0mmHg [IQR 8.5-
12.0] vs. 9.0mmHg [IQR 7.0-12.0], p¼0.11, respectively).
CONCLUSION TAVI in VSB resulted in similar clinical outcomes with
effective post-procedural hemodynamics compared with NB patients.
Care should be taken to avoid vascular complications in smaller body
size patients with smaller vascular access.
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BACKGROUND Although Mitral Cerclage Annuloplasty has shown the
excellent efﬁcacy of reducing mitral regurgitation, the potential risk
of surrounding tissue erosion and /or its consequent conduction block
by thin suture are still becoming barrier to human translation. Here, in
this preclinical study, we aimed to prove the concept of a novel
approach (mitralloop cerclage, MLC) that is specially designed to
prevent these shortcomings.
METHODS MLC consists of (1) a novel appliance called \’coronary
sinus and tricuspid valve protective device(CSTV)\’ with the tension
locker and (2) the nylon coated braided stainless rope (0.6mm in
thickness) with a coronary artery protective device in a single unit
(cerclage rope). The outer surface of CSTV is coated with ePTFE.
Tension locking was made at the tip of CSTV stem with a specially
designed tension stopper. Other procedure related dedicated de-
vices were also developed and used for MLC procedure. MLC pro-
cedure was almost the same as that of mitral cerclage annuloplasty.
However, the delivering the CSTV though the cerclage rope was an
added step on mitral cerclage annuloplasty. Total 9 healthy farm
swine underwent MLC in short-term (2 weeks, n¼4) and mid-term
(6 weeks, n¼5) survival experiments. The mature prototype for
human trial was used in mid-term group. X-ray ﬂuoroscopy was
used for imaging guidance for the procedure. Echocardiogram
and cardiac CT were checked before the procedure and during
follow-up.
RESULTS Procedural success rate was 100%. MLC resulted in signiﬁ-
cant reduction of septal lateral dimension of mitral annulus (24.58
2.16. vs. 21.26 1.43 mm, p¼0.04) and LV volume (75.9 3.9 vs. 70.6 5.0 ml, p¼0.04, in diastole) in mid-term group (n¼5). No any other
serious complication was noted except trivial TR in all cases (n¼9).
Conduction abnormality was not noted either (n¼9). LV ejection
fraction was not deteriorated during 6 week follow-up (63.73.7 in
baseline vs. 68.6 1.4 % in MLC, p¼0.08, n¼5). Necropsy ﬁndings
showed no evidence of tissue erosion and excellent biocompatibility
of the implanted devices.
CONCLUSION MLC, as a novel approach of catheter based MV repair,
appeared to be feasible and effective without raising any signiﬁcant
safety issues. This promising preclinical result could warrant human
translation.VULNERABLE PLAQUE DIAGNOSIS AND TREATMENT
(TCTAP A-124)
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BACKGROUND Macrophages activities play very important roles in
the function of stability on atherosclerotic coronary plaque. Rho ki-
nase, one of the small GTPase family proteins, has been considered a
pathophysiological role in the development of atherosclerosis. How-
ever, it remains unclear the role of Rho-kinase activity and expression
of macrophages when the acute myocardial infarction (AMI) occurs.
The aims of current study were: 1) To test whether Rho kinase level in
peripheral blood increased in AMI patients; 2) To measure the asso-
ciation between circulating macrophages and their Rho kinase protein
expression on the plaques.
METHODS We enrolled patients with AMI (<24 hours of onset),
receiving emergency procedure of cardiac catheterization. We ﬁrst
collected their leukocytes to detect the level of Rho kinase activity.
The expression of macrophage (CD68), Rho kinase activity was
measured by immunohistochemistry (IHC) on the plaques aspirated
from the Thrombuster catheter. We also performed ﬂow cytometry
and PCR analysis on the macrophages isolated from the peripheral
blood.
RESULTS Twenty-ﬁve patients (80% male in gender; mean 65  14
years of age) were diagnosed with AMI and enrolled in our study. The
Rho kinase activity of leukocytes, deﬁned as protein expression ratio
of phospho-MBS/total MBS, was higher compared with our previous
observed normal ones (AMI vs. normal: 3.1 vs.1.2, p<0.001). We also
observed pathologically rich macrophages in human coronary plaque
rupture. Interestingly, the expression of Rho kinase activity was also
higher and localized similarly to the macrophages by IHC stains.
Finally, macrophages isolated from AMI patients also had higher
expression of Rho (RhoA, RhoB and Cdc42) and ERM (ezrin, moesin)
and proteins (all p<0.05).
CONCLUSION During AMI, macrophages are actively expressed. AMI
patients have high Rho kinase activity both on coronary vulnerable
plaques and peripheral blood. These molecular insights provide us a
future potential therapeutic target.
